Liu et al. reported two cases of patients with BRC resistant prolactinomas who exhibited reduced PRL levels and significant tumour shrinkage when a combination of BRC and metformin was administered [8]. This evidence concerns the gene PRL and prolactin-producing pituitary gland adenoma.